Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 9/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.68 |
| ▸ | BAX | Q07812 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | RAD52 | P43351 | 1/20 | 0.52 |
| ▸ | PER2 | O15055 | 3/20 | 0.50 |
| ▸ | CRY1 | Q16526 | 3/20 | 0.50 |
| ▸ | CRY2 | Q49AN0 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Wiskostatin SCHEMBL5800361 | 1.00 | DNM1 (1.00) | DNM1MAPTSMN1; SMN2P2RX3BAX | |
| Wiskostatin SCHEMBL21067493 | 1.00 | DNM1 (1.00) | DNM1MAPTSMN1; SMN2P2RX3BAX | |
| SCHEMBL410834 | 0.85 | DNM1 (0.73) | DNM1MAPTSMN1; SMN2P2RX3BAX | |
| SCHEMBL22830722 | 0.85 | P2RX3 (0.76) | DNM1MAPTSMN1; SMN2P2RX3BAX | |
| SCHEMBL21467809 | 0.83 | DNM1 (0.71) | DNM1MAPTSMN1; SMN2P2RX3PER2 | |
| SCHEMBL15592978 | 0.83 | DNM1 (0.70) | DNM1MAPTSMN1; SMN2P2RX3BAX | |
| SCHEMBL15880984 | 0.82 | DNM1 (0.69) | DNM1MAPTSMN1; SMN2HTTNPSR1 | |
| SCHEMBL25076450 | 0.81 | P2RX3 (1.00) | DNM1MAPTSMN1; SMN2P2RX3BAX | |
| SCHEMBL12013711 | 0.81 | DNM1 (0.68) | DNM1MAPTSMN1; SMN2P2RX3BAX | |
| SCHEMBL30267744 | 0.81 | DNM1 (0.68) | DNM1MAPTSMN1; SMN2P2RX3BAX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022191812-A1 | METHOD OF FACILITATING WOUND-INDUCED HAIR FOLLICLE NEOGENESIS, TISSUE REGENERATION AND REDUCING WOUND STIFFNESS | NATIONAL CHENG KUNG UNIVERSITY (TW) | 2022-09-15 | — | — | WO | claimed |
| EP-4715043-A1 | METHOD FOR PRODUCING NEURAL CREST CELLS | Kyoto University (JP) | 2026-03-25 | — | — | EP | disclosed |
| EP-4713688-A2 | HUMAN EIF3L BINDING MOLECULES AND CANCER EXOSOME DIAGNOSTICS AND ANTI-THROMBOTIC TREATMENT | The Cleveland Clinic Foundation (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12527746-B2 | Peptide/particle delivery systems | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4346928-B1 | BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST WEAKLY ADHERENT CELLS | US HEALTH (US) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024243152-A2 | HUMAN EIF3L BINDING MOLECULES AND CANCER EXOSOME DIAGNOSTICS AND ANTI-THROMBOTIC TREATMENT | THE CLEVELAND CLINIC FOUNDATION (US) | 2024-11-28 | — | — | WO | disclosed |
| US-20240271089-A1 | METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-08-15 | — | — | US | disclosed |
| US-20240261474-A1 | BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST WEAKLY ADHERENT CELLS | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-08-08 | — | — | US | disclosed |
| CN-111542598-B | Pluripotent stem cell aggregation inhibitor | 株式会社钟化 | 2024-07-30 | — | — | CN | disclosed |
| EP-3427734-B1 | COMPOSITIONS COMPRISING AN ANTI-ANGIOGENIC AGENT FOR USE IN AMELIORATING SYMPTOMS OF ALZHEIMER'S DISEASE | ALTERNATIVE EXTRACTS INC (CA) | 2024-07-10 | — | — | EP | disclosed |
| US-20240100018-A1 | COMPOUNDS FOR THE TREATMENT OF A DISEASE OR DISORDER, METHODS FOR IDENTIFYING SAID COMPOUNDS | CEDARS-SINAI MEDICAL CENTER | 2024-03-28 | — | — | US | disclosed |
| US-11925678-B2 | Methods for diagnosing and treating Alzheimer's disease | Cava Healthcare Inc. (CA) | 2024-03-12 | — | — | US | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230218577-A1 | USE OF HEAT SHOCK PROTEIN INHIBITORS FOR THE TREATMENT OF NEURODEVELOPMENTAL DISORDERS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230210937-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND/OR PROPHYLAXIS OF DIABETES AND OTHER CONDITIONS | LIFELOCK BIOSCIENCE SOLUTIONS INC. (CA) | 2023-07-06 | — | — | US | disclosed |
| US-20230135501-A1 | GENE THERAPY | UCL BUSINESS LTD (GB) | 2023-05-04 | — | — | US | disclosed |
| EP-4106875-A1 | GENE THERAPY | UCL Business Ltd (GB) | 2022-12-28 | — | — | EP | disclosed |
| WO-2022191812-A1 | METHOD OF FACILITATING WOUND-INDUCED HAIR FOLLICLE NEOGENESIS, TISSUE REGENERATION AND REDUCING WOUND STIFFNESS | NATIONAL CHENG KUNG UNIVERSITY (TW) | 2022-09-15 | — | — | WO | disclosed |
| US-20220267736-A1 | PLURIPOTENT STEM CELL AGGREGATION SUPPRESSOR | KANEKA CORPORATION (JP) | 2022-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527746-B2 | Peptide/particle delivery systems | VEGFA, IGF2BP2, MSTN | DNM1 2263/4885MAPT 1591/4885SMN1; SMN2 644/4885 |
| US-20230218577-A1 | USE OF HEAT SHOCK PROTEIN INHIBITORS FOR THE TREATMENT OF NEURODEVELOPMENTAL DISORDERS | HSP90AB1, HSP90AA1, HSF1 | DNM1 1162/4885MAPT 71/4885SMN1; SMN2 678/4885 |
| US-20230210937-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND/OR PROPHYLAXIS OF DIABETES AND OTHER CONDITIONS | FBP1, PPIP5K2, IP6K1 | DNM1 1815/4885MAPT 2644/4885SMN1; SMN2 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.